Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
Metrics: PDF 1110 views | HTML 1954 views | ?
Meizhen Xu1,*, Yina Liu1,*, Dan Li2,3,6,*, Xuelin Wang4, Shuang Liang5, Gaochuan Zhang1 and Xiaoqin Yang1
1School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China
2Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
3School of Life Science and Technology, Tongji University, Shanghai, China
4Yushan Town, Kunshan, China
5Scotch Plains, New Jersey, USA
6Present address: Jiayin BioTechnology Co., Ltd., Shanghai, China
*These authors contributed equally to this work
Gaochuan Zhang, email: [email protected]
Xiaoqin Yang, email: [email protected]
Keywords: ERCC5, polymorphism, cancer, meta-analysis, platinum-based chemotherapy
Received: November 23, 2016 Accepted: June 17, 2017 Published: July 04, 2017
It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy. This meta-analysis was performed to summarize the scattered evidence regarding the association between these two polymorphisms and sensitivity to platinum-based treatment. Thirteen studies were included after a comprehensive literature search. The pooled odds ratios and 95% confidence intervals suggested that the C allele of the ERCC5 rs1047768 polymorphism is associated with elevated sensitivity to platinating agents, especially for Chinese patients. However, no difference among rs17655 genotypes could be detected.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.